Where do CytomX Therapeutics's ratios come from?

Every ratio is computed from CytomX Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Profitability
Operating margin	-181.9%-206pp	-29.4%-47.4pp	20.5%+15.2pp	30.6%+25.8pp	24.4%+15.3pp
Net margin	-166.4%—	-22.8%—	24.7%—	——	——
Efficiency
Asset turnover	0.2×-0.9×	0.6×-0.3×	0.8×+0.1×	0.8×+0.2×	1×+0.5×
Liquidity
Current ratio	10.4×+8.7×	3.1×+1.8×	3.6×+2.6×	4.2×+3.2×	1.7×+0.6×
Leverage
Debt-to-equity	0×—	0×—	——	——	——
Per Share
Book value per share	$1.80+528%	$0.72+13,393%	$0.65+336%	$0.93+353%	$0.29+175%
Valuation
Market capitalization	$711.89M+94.8%	$721.79M+795%	$526.07M+471%	$337.14M+255%	$50.93M-65.5%
Price / sales	20×+17.6×	9.5×+8.9×	4.6×+3.9×	2.4×+1.6×	0.3×-0.9×
Price / book	2.2×-12.4×	7.3×—	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about CytomX Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

Where do CytomX Therapeutics's ratios come from?: Every ratio is computed from CytomX Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.